Merlin Piscitelli

CRO EMEA at Datasite      


A seasoned Sales Leader and Sales Professional with 20+ years’ experience growing companies, leading high performance sales teams and exceeding expectations.

My experience is primarily in high-growth companies in leading Software, SaaS and Cloud based technologies & services with a client base of Fortune 500 companies, world leading Law Firms, Investment Banks, Financial Advisors and Private Equity professionals throughout EMEA and North America.

2018 marks my 12th year at Merrill Corporation, 9 years as top producer in the company worldwide and 3 years managing Europe, Middle East and Africa (EMEA) Sales organization which is the most productive and highest growth region, top and bottom line, across the organization.

Contributing Author

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Articles from Merlin

Cautious Optimism in 2024 for Healthcare M&A

   484
Cautious Optimism in 2024 for Healthcare M&A

2024 was supposed to mark the start of a significant comeback for healthcare mergers and acquisitions (M&A). Yet with the first half of the year at an end, the anticipated resurgence is uncertain. Still, there are some promising signs, and regional variances are providing a hopeful outlook for the remainder of the year.